Document is current
Any future updates will be listed below
-
Authors
Zimmer, Kai
Kocher, Florian
Untergasser, Gerold
Kircher, Brigitte http://orcid.org/0000-0003-1624-2664
Amann, Arno
Baca, Yasmine
Xiu, Joanne
Korn, W. Micheal http://orcid.org/0000-0002-0124-6841
Berger, Martin D.
Lenz, Heinz-Josef http://orcid.org/0000-0003-2178-9568
Puccini, Alberto http://orcid.org/0000-0002-2492-4043
Fontana, Elisa
Shields, Anthony F.
Marshall, John L.
Hall, Michael
El-Deiry, Wafik S.
Hsiehchen, David
Macarulla, Teresa
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Pichler, Renate
Khushman, Moh’d
Manne, Upender
Lou, Emil
Wolf, Dominik
Sokolova, Viktorija
Schnaiter, Simon
Zeimet, Alain G.
Gulhati, Pat
Widmann, Gerlig
Seeber, Andreas http://orcid.org/0000-0001-8529-7824
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 31 May 2023
First Online: 3 July 2023
Competing interests
: Y.B. is an employee of Caris Life Sciences. J.X. is an employee of Caris Life Sciences. A.F.S. reports research support provided by Caris Life Sciences for genomic analysis. J.L.M. reports personal fees from Caris Life Science, Indivumed, Bayer, Merck, Taiho, and Pfizer outside the submitted work. M.H. reports other support from Caris during the conduct of the study; and personal fees from Eisai and Natera outside the submitted work; in addition, M.H. has a patent for hereditary risk detection issued; and collaborative research only (no financial support or grants or fees) with the following: Myriad, Invitae. W.M.K. reports Caris Life Sciences employment and stock ownership. E.L. reports research grants from the American Association for Cancer Research (AACR-Novocure Tumor-Treating Fields Research Award, Grant Number 19-60-62-LOU); American Cancer Society Research Scholar Grant RSG-22-022-01-CDP; and the Minnesota Ovarian Cancer Alliance in 2019, 2021, and 2022; honorarium and travel expenses for a research talk at GlaxoSmithKline in 2016; honoraria and travel expenses for lab-based research talks, and equipment for laboratory-based research, Novocure, Ltd, 2018-2021; honorarium for panel discussion organized by Antidote Education for a CME module on diagnostics and treatment of HER2<sup>+</sup> gastric and colorectal cancers, funded by Daiichi Sankyo, 2021 (honorarium donated to lab); consultant, Nomocan Pharmaceuticals (unpaid); Scientific Advisory Board Member, Minnetronix, LLC, 2018-present (unpaid); consultant and speaker honorarium, Boston Scientific US, 2019; institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the NCI, and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (unpaid); A.S. reports other support from Caris Life Sciences during the conduct of the study. W.A.-D. reports other support from Caris Life Sciences Precision Oncology Alliance. The remaining authors declare no competing interests.
